세계의 불임 치료 서비스 시장 전망(-2027년)

Market Overview

The primary market drivers accelerating market expansion are rising levels of stress, obesity, frequent smoking, and environmental variables. There is a significant need for fertilization services as a result of a number of social and environmental issues, including lifestyle modifications such as anxiety or depression, overweight, and heavy alcohol consumption. For instance, 4% fewer children were born in the nation in 2020 compared to 2019, as per NPR, a semi media institution in the US. At 55.8 births per 1,000 women aged between 15 to 44, according to preliminary data, the total fertility rate reached yet another record low. When infertility rates rise, there will be a greater need for fertility services.

Segment Overview

Underlying reason, Therapy type, and Regional Insights are the three types of segment insights that make up Global Fertility Services.

Male and female infertility are included in the market segmentation for fertility services based on the underlying cause.

The market data for fertility services has been divided by medication taken into ART and insufficiency medications.

The high percentage is attributed to a rise in the infertile rate, increased awareness of fertility services, technological advancements, and supportive government initiatives.

Regional Analysis

The analysis offers market insights for North America, Europe, Asia-Pacific, and the rest of the world, by region. The market for fertility services in Europe, which had sales of $ 12.6871 billion in 2021, is anticipated to rise at a substantial CAGR throughout the study period. The high percentage is attributed to a rise in the failure rate, increased awareness of fertility services, technological advancements, and supportive government initiatives. For instance, per the European Society of Reproductive Biology and Embryology, the European Union does have the highest proportion of infertile in the world, affecting almost 25 million people. North America is expected to expand significantly during the projection period.

Major Players

The Global Fertility Service Sector is home to a variety of businesses, including the Irvine Scientific Company Inc., Cook Medical, Vitrolife, Monash IVF Group, Ferring B. V, Kitazato Cooperative, and Care Fertility, among others.

COVID 19 Impacts

The COVID-19 pandemic initially had a negative impact on the market for fertility services, but it quickly rebounded with a boost as many governments encouraged the restoration of infertility clinics, according to The Business Research Company's estimate of the worldwide fertility services industry. Since they followed the rules that were logistically feasible in their clinical setup, aligned their protocols with their hospital regulations, and was in agreement with the views of their clinical leaders, many people were seeking intending to go to infertility centres. Future COVID-19 immunisation rates are predicted to improve, which will benefit the market for fertility services because many nations are already in the unlocking stage and couples seeking treatment won't need to put off their plans. The rise in same-sex marriages is one of the main factors contributing to the market's explosive expansion, and it is anticipated that this trend will continue during the projection period. By using Partnership IVF, a type of IVF for lesbian couples that allows both partners to become physically active in the creation of their kid, same-sex couples will have a good impact on the IVF services. In this procedure, one partner provides the eggs, which are fertilised by sperm donation, and the other partner becomes pregnant. The market for fertility services will therefore grow as a result of the rise in same-sex unions.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW 13
  • 1.1.1 MARKET SYNOPSIS 13

2 MARKET INTRODUCTION

• 2.1 SCOPE OF THE STUDY 14
• 2.2 RESEARCH OBJECTIVE 14
• 2.3 LIST OF ASSUMPTIONS & LIMITATIONS 14

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW 16
• 3.2 DATA MINING 16
• 3.3 SECONDARY RESEARCH 17
• 3.4 PRIMARY RESEARCH 18
  • 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 18
  • 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 19
• 3.5 FORECASTING TECHNIQUES 20
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21
  • 3.6.1 BOTTOM-UP APPROACH 22
  • 3.6.2 TOP-DOWN APPROACH 22
• 3.7 DATA TRIANGULATION 23
• 3.8 VALIDATION 23

4 MARKET DYNAMICS

• 4.1 OVERVIEW 24
• 4.2 DRIVERS 25
  • 4.2.1 GROWTH IN THE MEDIAN AGE OF FIRST-TIME MOTHERHOOD AND DECLINING FERTILITY RATE 25
  • 4.2.2 TECHNOLOGICAL ADVANCEMENTS IN FERTILITY TREATMENT 25
  • 4.2.3 INCREASING PREVALENCE OF OBESITY AND CONSUMPTION OF ALCOHOL/CIGARETTES 25
  • 4.2.4 DRIVERS IMPACT ANALYSIS 26
• 4.3 RESTRAINTS 26
  • 4.3.1 HIGH PROCEDURAL COSTS OF ASSISTED REPRODUCTIVE TECHNIQUES IN DEVELOPED MARKETS 26
  • 4.3.2 ETHICAL AND SOCIAL CONCERNS 27
  • 4.3.3 RESTRAINTS IMPACT ANALYSIS 27
• 4.4 OPPORTUNITIES 28
  • 4.4.1 REIMBURSEMENT FOR FERTILITY TREATMENTS 28

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL 29
  • 5.1.1 THREAT OF NEW ENTRANTS 29
  • 5.1.2 BARGAINING POWER OF SUPPLIERS 30
  • 5.1.3 THREAT OF SUBSTITUTES 30
  • 5.1.4 BARGAINING POWER OF BUYERS 30
  • 5.1.5 INTENSITY OF RIVALRY 30
• 5.2 VALUE CHAIN ANALYSIS 31
  • 5.2.1 R&D AND DESIGNING 31
  • 5.2.2 MANUFACTURING 32
  • 5.2.3 DISTRIBUTION 32
  • 5.2.4 MARKETING & SALES 32
  • 5.2.5 POST-SALES MONITORING 32
• 5.3 COVID-19 IMPACT ANALYSIS 33
  • 5.3.1 IMPACT ON GROWTH RATE 33
  • 5.3.2 IMPACT ON MAJOR PLAYERS 33
  • 5.3.3 IMPACT ON MAJOR REGIONS 33

6 GLOBAL FERTILITY SERVICES MARKET, BY UNDERLYING CAUSE

• 6.1 OVERVIEW 34
• 6.2 FEMALE INFERTILITY 35
• 6.3 MALE INFERTILITY 36

7 GLOBAL FERTILITY SERVICES MARKET, BY TREATMENT TYPE

• 7.1 OVERVIEW 37
• 7.2 ASSISTED REPRODUCTIVE TECHNOLOGY (ART) 38
  • 7.2.1 IN-VITRO FERTILIZATION (IVF) 39
  • 7.2.2 FROZEN EMBRYO REPLACEMENT (FER) 39
  • 7.2.3 ARTIFICIAL INSEMINATION 40
  • 7.2.4 OTHERS 40
• 7.3 INFERTILITY DRUGS 41

8 GLOBAL FERTILITY SERVICES MARKET, BY REGION

• 8.1 OVERVIEW 42
• 8.2 EUROPE 43
  • 8.2.1 WESTERN EUROPE 45
    • 8.2.1.1 GERMANY 46
    • 8.2.1.2 UK 47
    • 8.2.1.3 FRANCE 48
    • 8.2.1.4 ITALY 49
    • 8.2.1.5 SPAIN 50
    • 8.2.1.6 REST OF WESTERN EUROPE 51
  • 8.2.2 EASTERN EUROPE 52
• 8.3 AMERICAS 54
  • 8.3.1 NORTH AMERICA 56
    • 8.3.1.1 US 57
    • 8.3.1.2 CANADA 58
  • 8.3.2 LATIN AMERICA 59
• 8.4 ASIA-PACIFIC 61
  • 8.4.1 JAPAN 62
  • 8.4.2 CHINA 63
  • 8.4.3 INDIA 64
  • 8.4.4 SOUTH KOREA 65
  • 8.4.5 AUSTRALIA 66
  • 8.4.6 REST OF ASIA PACIFIC 67
• 8.5 MIDDLE EAST & AFRICA 69
  • 8.5.1 MIDDLE EAST 70
  • 8.5.2 AFRICA 71

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW 73
• 9.2 MAJOR PLAYERS IN THE GLOBAL FERTILITY SERVICES MARKET 73
• 9.3 COMPETITIVE BENCHMARKING 74
• 9.4 COMPETITOR DASHBOARD 75
• 9.5 DEVELOPMENTS IN THE GLOBAL FERTILITY SERVICES MARKET 76
  • 9.5.1 ACQUISITION 76
  • 9.5.2 COLLABORATION 76
  • 9.5.3 EXPANSION 76
  • 9.5.4 DEVELOPMENT 77
  • 9.5.5 JOINT VENTURE 77
  • 9.5.6 PRODUCT LAUNCH/PRODUCT APPROVAL 77

10 COMPANY PROFILES

• 10.1 MERCK KGAA 78
  • 10.1.1 COMPANY OVERVIEW 78
  • 10.1.2 FINANCIAL OVERVIEW 79
  • 10.1.3 PRODUCTS/SERVICES OFFERED 79
  • 10.1.4 KEY DEVELOPMENTS 80
  • 10.1.5 SWOT ANALYSIS 80
  • 10.1.6 KEY STRATEGIES 81
• 10.2 COOPERSURGICAL, INC. 82
  • 10.2.1 COMPANY OVERVIEW 82
  • 10.2.2 FINANCIAL OVERVIEW 83
  • 10.2.3 PRODUCTS/SERVICES OFFERED 83
  • 10.2.4 KEY DEVELOPMENTS 84
  • 10.2.5 SWOT ANALYSIS 85
  • 10.2.6 KEY STRATEGIES 85
• 10.3 CARE FERTILITY 86
  • 10.3.1 COMPANY OVERVIEW 86
  • 10.3.2 FINANCIAL OVERVIEW 86
  • 10.3.3 PRODUCTS/SERVICES OFFERED 86
  • 10.3.4 KEY DEVELOPMENTS 87
  • 10.3.5 SWOT ANALYSIS 87
  • 10.3.6 KEY STRATEGIES 87
• 10.4 FERRING BV. 88
  • 10.4.1 COMPANY OVERVIEW 88
  • 10.4.2 FINANCIAL OVERVIEW 88
  • 10.4.3 PRODUCTS/SERVICES OFFERED 88
  • 10.4.4 KEY DEVELOPMENTS 89
  • 10.4.5 SWOT ANALYSIS 89
  • 10.4.6 KEY STRATEGIES 89
• 10.5 INVO BIOSCIENCE 90
  • 10.5.1 COMPANY OVERVIEW 90
  • 10.5.2 FINANCIAL OVERVIEW 90
  • 10.5.3 PRODUCTS/SERVICES OFFERED 90
  • 10.5.4 KEY DEVELOPMENTS 91
  • 10.5.5 SWOT ANALYSIS 91
  • 10.5.6 KEY STRATEGIES 91
• 10.6 VITROLIFE 92
  • 10.6.1 COMPANY OVERVIEW 92
  • 10.6.2 FINANCIAL OVERVIEW 92
  • 10.6.3 PRODUCTS/SERVICES OFFERED 93
  • 10.6.4 KEY DEVELOPMENTS 94
  • 10.6.5 SWOT ANALYSIS 95
  • 10.6.6 KEY STRATEGIES 95
• 10.7 MONASH IVF GROUP 96
  • 10.7.1 COMPANY OVERVIEW 96
  • 10.7.2 FINANCIAL OVERVIEW 96
  • 10.7.3 PRODUCTS/SERVICES OFFERED 97
  • 10.7.4 KEY DEVELOPMENTS 97
  • 10.7.5 SWOT ANALYSIS 98
  • 10.7.6 KEY STRATEGIES 98
• 10.8 COOK 99
  • 10.8.1 COMPANY OVERVIEW 99
  • 10.8.2 FINANCIAL OVERVIEW 99
  • 10.8.3 PRODUCTS/SERVICES OFFERED 99
  • 10.8.4 KEY DEVELOPMENTS 100
  • 10.8.5 SWOT ANALYSIS 101
  • 10.8.6 KEY STRATEGIES 101
• 10.9 FUJIFILM IRVINE SCIENTIFIC 102
  • 10.9.1 COMPANY OVERVIEW 102
  • 10.9.2 FINANCIAL OVERVIEW 102
  • 10.9.3 PRODUCTS/SERVICES OFFERED 103
  • 10.9.4 KEY DEVELOPMENTS 103
  • 10.9.5 SWOT ANALYSIS 104
  • 10.9.6 KEY STRATEGIES 104
• 10.10 KITAZATO CORPORATION 105
  • 10.10.1 COMPANY OVERVIEW 105
  • 10.10.2 FINANCIAL OVERVIEW 105
  • 10.10.3 PRODUCTS/SERVICES OFFERED 105
  • 10.10.4 KEY DEVELOPMENTS 106
  • 10.10.5 SWOT ANALYSIS 106
  • 10.10.6 KEY STRATEGIES 106

11 APPENDIX

• 11.1 REFERENCES 107
• 11.2 RELATED REPORTS 107